Here’s what’s on the biotech calendar for July 19–July 26: 0 FDA decision dates, 2 trial catalysts, and 0 earnings reports from tracked companies. 🧪 Trial Catalysts & Milestones OSTX — 2026-07-21: CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL OSTX — 2026-07-24: Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents […]

Here’s what’s on the biotech calendar for July 12–July 19: 1 FDA decision dates, 3 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-07-17 CELC — a significant number of patients with HR+/HER2- advanced bre NDA 🧪 Trial Catalysts & Milestones OSTX — 2026-07-15: […]

Here’s what’s on the biotech calendar for July 5–July 12: 2 FDA decision dates, 0 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-07-07 VERA — IgAN in adults BLA 2026-07-11 CORT — Platinum-Resistant Ovarian Cancer <P STYLE=”margin- NDA 📡 Run-up Radar Highlights Stocks […]

Here’s what’s on the biotech calendar for June 28–July 5: 2 FDA decision dates, 15 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-06-29 UNCY — hyperphosphatemia in patients NDA 2026-06-30 VRDN — patients with TED BLA 🧪 Trial Catalysts & Milestones OSTX — […]

Here’s what’s on the biotech calendar for June 21–June 28: 0 FDA decision dates, 0 trial catalysts, and 0 earnings reports from tracked companies. 📡 Run-up Radar Highlights Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature): UNCY — NDA in 8 days, score 84/100 CELC — NDA in […]

OSTX dominates this week’s catalyst calendar with three trial readouts spanning solid tumors and hematologic malignancies, including a promising CAR-T study in relapsed AML. The week offers a lighter schedule overall, with only one distant PDUFA date for ACHV’s nicotine dependence treatment in mid-2026. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-06-20 […]

This week brings a focused slate of clinical readouts, with Osteoxenon (OSTX) commanding attention through two distinct oncology programs. The most intriguing catalyst may be OSTX’s CD33 CAR-T data in relapsed AML, as the competitive cellular therapy landscape continues evolving. SignalPoint’s exercise physiology study rounds out a lighter-than-usual catalyst calendar. 🧪 Trial Catalysts & Milestones […]